OptimizeRx Corp. (NASDAQ:OPRX – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the nine analysts that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $11.57.
Several brokerages recently weighed in on OPRX. Citigroup reiterated a “market outperform” rating on shares of OptimizeRx in a report on Tuesday, October 27th. Stifel Nicolaus set a $12.00 price objective on shares of OptimizeRx in a research note on Thursday, August 13th. Wall Street Zen downgraded shares of OptimizeRx from a “strong-buy” rating to a “buy” rating in a report on Monday, July 20th. B. Riley Financial upped their price objective on shares of OptimizeRx from $10.00 to $11.00 and gave the company a “buy” rating in a report on Tuesday, September 29th. Finally, UBS Group set a $11.00 target price on shares of OptimizeRx in a research report on Friday, August 14th.
View Our Latest Stock Analysis on OptimizeRx
Hedge Funds Weigh In On OptimizeRx
Institutional investors have recently modified their holdings of the stock. Hsbc Holdings PLC acquired a new stake in OptimizeRx during the first quarter worth about $85,000. Corient Private Wealth LP purchased a new position in OptimizeRx during the second quarter valued at approximately $77,000. Cetera Investment Advisers purchased a new position in OptimizeRx during the first quarter valued at approximately $173,000. State of Wyoming lifted its holdings in OptimizeRx by 234.6% in the first quarter. State of Wyoming now owns 35,251 shares of the company’s stock valued at $221,000 after acquiring an additional 24,716 shares during the period. Finally, Quantinno Capital Management LP lifted its holdings in OptimizeRx by 180.1% in the first quarter. Quantinno Capital Management LP now owns 49,022 shares of the company’s stock valued at $308,000 after acquiring an additional 31,518 shares during the period. Hedge funds and other institutional investors own 76.47% of the company’s stock.
OptimizeRx Stock Performance
Shares of OPRX opened at $8.76 on Monday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 5.58 and a current ratio of 5.58. The stock has a 50-day moving average of $8.35 and a two-hundred day moving average of $7.28. The stock has a market cap of $165.04 million, a P/E ratio of 38.09 and a beta of 1.20. OptimizeRx has a one year low of $4.54 and a one year high of $18.37.
OptimizeRx (NASDAQ:OPRX – Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported $0.16 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.05. OptimizeRx had a return on equity of 9.44% and a net margin of 4.66%. The business had revenue of $20.50 million for the quarter, compared to analyst estimates of $20.20 million. As a group, research analysts predict that OptimizeRx will post 0.49 EPS for the current year.
About OptimizeRx
OptimizeRx Corporation (NASDAQ: OPRX) is a digital health and life sciences technology company that helps pharmaceutical and biotechnology companies connect with healthcare professionals and patients. Its platform supports prescription-related communications, treatment access, affordability, adherence and patient engagement throughout the medication journey.
The company provides solutions that can be integrated into electronic health records and other healthcare workflows. Its offerings include point-of-care messaging for healthcare professionals, patient support and savings programs, medication access tools, and data and analytics services designed to help life sciences companies communicate with relevant audiences and understand engagement.
OptimizeRx was founded in 2006 and has primarily served the U.S.
Featured Stories
- Five stocks we like better than OptimizeRx
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
- The Ugly Truth Behind SoundHound’s Q3 Results
Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.
